BOULDER, Colo.--(BUSINESS WIRE)--Today, ArcherDX launched Archer™ PreSeq™ QC Assays, which assess the quality of nucleic acid in FFPE samples prior to library creation for next-generation sequencing (NGS)-based mutation detection. “NGS is an extremely effective way to find oncogenic driver mutations in a tumor specimen, but analytical sensitivity and specificity are dependent upon the quality of the sample. PreSeq assays provide users the ability to assess the quality of nucleic acid in a specimen before beginning time-consuming and costly library preparation,” says Josh Stahl, Vice-President of R&D and Scientific Operations at ArcherDX.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
